Page 21 of 32 – SEC Filing The following constitutes Amendment No. 3 to the Schedule 13D filed by the undersigned (“Amendment No. 3”). This Amendment No. 3 amends the Schedule 13D as specifically set forth herein. Item 2. Identity and Background.
Item 2 is hereby amended and restated to read as follows:
(a) This statement is filed by: (i) Starboard Value and Opportunity Master Fund Ltd, a Cayman Islands exempted company (“Starboard V&O Fund”), with respect to the Shares directly and beneficially owned by it;
(ii) Starboard Value and Opportunity S LLC, a Delaware limited liability company (“Starboard S LLC”), with respect to the Shares directly and beneficially owned by it;
(iii) Starboard Value and Opportunity C LP, a Delaware limited partnership (“Starboard C LP”), with respect to the Shares directly and beneficially owned by it;
(iv) Starboard Value R LP (“Starboard R LP”), as the general partner of Starboard C LP;
(v) Starboard Value R GP LLC (“Starboard R GP”), as the general partner of Starboard R LP;
(vi) Starboard Value LP (“Starboard Value LP”), as the investment manager of Starboard V&O Fund, Starboard C LP and of a certain managed account (the “Starboard Value LP Account”) and the manager of Starboard S LLC;
(vii) Starboard Value GP LLC (“Starboard Value GP”), as the general partner of Starboard Value LP;
(viii) Starboard Principal Co LP (“Principal Co”), as a member of Starboard Value GP;
(ix) Starboard Principal Co GP LLC (“Principal GP”), as the general partner of Principal Co;
(x) Jeffrey C. Smith, as a member of Principal GP and as a member of each of the Management Committee of Starboard Value GP and the Management Committee of Principal GP and as a nominee for the Board of Directors of the Issuer (the “Board”);
(xi) Mark R. Mitchell, as a member of Principal GP and as a member of each of the Management Committee of Starboard Value GP and the Management Committee of Principal GP;
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
The following constitutes Amendment No. 3 to the Schedule 13D filed by the undersigned (“Amendment No. 3”). This Amendment No. 3 amends the Schedule 13D as specifically set forth herein.
| Item 2. | Identity and Background. |
| | Item 2 is hereby amended and restated to read as follows: |
(a) This statement is filed by:
| | (i) | Starboard Value and Opportunity Master Fund Ltd, a Cayman Islands exempted company (“Starboard V&O Fund”), with respect to the Shares directly and beneficially owned by it; |
| | (ii) | Starboard Value and Opportunity S LLC, a Delaware limited liability company (“Starboard S LLC”), with respect to the Shares directly and beneficially owned by it; |
| | (iii) | Starboard Value and Opportunity C LP, a Delaware limited partnership (“Starboard C LP”), with respect to the Shares directly and beneficially owned by it; |
| | (iv) | Starboard Value R LP (“Starboard R LP”), as the general partner of Starboard C LP; |
| | (v) | Starboard Value R GP LLC (“Starboard R GP”), as the general partner of Starboard R LP; |
| | (vi) | Starboard Value LP (“Starboard Value LP”), as the investment manager of Starboard V&O Fund, Starboard C LP and of a certain managed account (the “Starboard Value LP Account”) and the manager of Starboard S LLC; |
| | (vii) | Starboard Value GP LLC (“Starboard Value GP”), as the general partner of Starboard Value LP; |
| | (viii) | Starboard Principal Co LP (“Principal Co”), as a member of Starboard Value GP; |
| | (ix) | Starboard Principal Co GP LLC (“Principal GP”), as the general partner of Principal Co; |
| | (x) | Jeffrey C. Smith, as a member of Principal GP and as a member of each of the Management Committee of Starboard Value GP and the Management Committee of Principal GP and as a nominee for the Board of Directors of the Issuer (the “Board”); |
| | (xi) | Mark R. Mitchell, as a member of Principal GP and as a member of each of the Management Committee of Starboard Value GP and the Management Committee of Principal GP; |
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
Follow Assertio Therapeutics Inc (NASDAQ:ASRT)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
